Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

被引：3
|
作者：
Sampath, Deepak [1 ]
Herter, Sylvia [2 ]
Ingalla, Ellen [1 ]
Herting, Frank [3 ]
Bacac, Marina [2 ]
Nannini, Michelle [1 ]
Fairbrother, Wayne J. [1 ]
Klein, Christian [4 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Roche, Penzburg, Germany
[3] Roche Diagnost, Penzburg, Germany
[4] Roche Glycart AG, Schlieren, Switzerland
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-A245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A245
引用
下载
收藏
页数：2
相关论文
共 12 条
  • [1] Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity
    Herting, Frank
    Herter, Sylvia
    Friess, Thomas
    Lehmann, Christian
    Bacac, Marina
    Dangl, Markus
    Klein, Christian
    BLOOD, 2014, 124 (21)
  • [2] Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
    Erting, Frank H.
    Friess, Thomas
    Bader, Sabine
    Muth, Gunter
    Hoelzlwimmer, Gabriele
    Rieder, Natascha
    Umana, Pablo
    Klein, Christian
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2151 - 2160
  • [3] Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263
    Herting, Frank
    Bader, Sabine
    Umana, Pablo
    Klein, Christian
    BLOOD, 2010, 116 (21) : 1597 - 1597
  • [4] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    Advances in Therapy, 2017, 34 : 324 - 356
  • [5] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [6] COMBINATION OF THE GLYCOENGINEERED TYPE II CD20 ANTIBODY OBINUTUZUMAB WITH THE NOVEL BCL-2 SELECTIVE INHIBITOR VENETOCLAX INDUCES ROBUST CELL DEATH IN NHL MODELS AND CLL PATIENT SAMPLES
    Sampath, D.
    Herter, S.
    Ingalla, E.
    Herting, F.
    Friess, T.
    Bacac, M.
    Umana, P.
    Fairbrother, W.
    Ysebaert, L.
    Anne-Quillet, M.
    Klein, C.
    HAEMATOLOGICA, 2016, 101 : 568 - 568
  • [7] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [8] Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
    Herting, Frank
    Herter, Sylvia
    Friess, Thomas
    Muth, Gunther
    Bacac, Marina
    Sulcova, Jitka
    Umana, Pablo
    Dangl, Markus
    Klein, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (05) : 461 - 470
  • [9] Obinutuzumab (GA101): A novel type II glycoengineered CD20 antibody exhibits enhanced cell death against Rituximab-resistant and -sensitive cell lines in B-cell non-Hodgkin lymphoma
    Tiwari, Aradhana Awasthi
    Ayello, Janet
    Van de Ven, Carmella
    Cairo, Mitchell S.
    CANCER RESEARCH, 2012, 72
  • [10] GA101, a novel humanized type IICD20Antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo
    Umana, Pablo
    Ekkehard, Moessner
    Peter, Bruenker
    Gabriele, Klingner
    Ursula, Puentener
    Suter, Tobias
    Grau, Roger
    Schmidt, Carla
    Herter, Sylvia
    Gerdes, Christian
    Nopora, Adam
    Patre, Monika
    Moser, Samuel
    Sondermann, Peter
    Wheat, Luise
    Dyer, Martin J. S.
    Poppema, Sibrand
    Bauer, Sabine
    Kubbies, Manfred
    Strein, Pamela
    Fertig, Georg
    Friess, Thomas
    Dabbagh, Karim
    DalPorto, Joe
    Klein, Christian
    BLOOD, 2007, 110 (11) : 694A - 694A
12